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Abstract 26 
Aldehyde dehydrogenases participate in a variety of cellular homeostatic mechanisms 27 
like metabolism, proliferation, differentiation, apoptosis, whereas recently, they have 28 
been implicated in normal and cancer cell stemness. We explored roles for ALDH3A1 29 
in conferring resistance to chemotherapeutics/radiation/oxidative stress and whether 30 
ectopic overexpression of ALDH3A1 could lead to alterations of gene expression 31 
profile associated with cancer stem cell-like phenotype. MCF-7 cells were stably 32 
transfected either with an empty vector (mock) or human aldehyde dehydrogenase 33 
3A1 cDNA. The expression of aldehyde dehydrogenase 3A1 in MCF-7 cells was 34 
associated with altered cell proliferation rate and enhanced cell resistance against 35 
various chemotherapeutic drugs (4-hydroxyperoxycyclophosphamide, doxorubicin, 36 
etoposide, and 5-fluorouracil). Aldehyde dehydrogenase 3A1 expression also led to 37 
increased tolerance of MCF-7 cells to gamma radiation and hydrogen peroxide-38 
induced stress. Furthermore, aldehyde dehydrogenase 3A1-expressing MCF-7 cells 39 
exhibited gene up-regulation of cyclins A, B1, B2, and down-regulation of cyclin D1 40 
as well as transcription factors p21, CXR4, Notch1, SOX2, SOX4, OCT4, and JAG1. 41 
When compared to mock cells, no changes were observed in mRNA levels of ABCA2 42 
and ABCB1 protein pumps with only a minor decrease of the ABCG2 pump in the 43 
aldehyde dehydrogenase 3A1-expressing cells. Also, the adhesion molecules EpCAM 44 
and CD49F were also found to be up-regulated in aldehyde dehydrogenase 45 
3A1expressing cells. Taken together, ALDH3A1 confers a multi-modality resistance 46 
phenotype in MCF-7 cells associated with slower growth rate, increased clonogenic 47 
capacity, and altered gene expression profile, underlining its significance in cell 48 
homeostasis.  49 
 50 
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1. Introduction  55 
Aldehyde dehydrogenase 3A1 (ALDH3A1) belongs to the broad family of aldehyde 56 
dehydrogenases (ALDHs). It is an NADP
(+)
-dependent enzyme, responsible for 57 
oxidizing medium chain saturated and unsaturated aldehydes to their corresponding 58 
carboxylic acids (Kim et al., 2014, Vasiliou et al., 2004, Vasiliou et al., 2000). 59 
Because of its ability to detoxify toxic aldehydes, by-products of lipid peroxidation 60 
like 4-hydroxy-2-nonenal (4-HNE), ALDH3A1 is considered an important component 61 
of cellular anti-oxidant defense (Black et al., 2012, Jang et al., 2014, Pappa et al., 62 
2003a, Pappa et al., 2003b, Voulgaridou et al., 2011). Apart from its essential 63 
metabolic function, it has been suggested that ALDH3A1 may have additional roles in 64 
cellular homeostasis (Kim, Lee, 2014, Voulgaridou et al., 2013) including those of 65 
cell cycle regulation and protection against apoptosis and DNA damage (Chen et al., 66 
2013, Estey et al., 2007, Jang, Bruse, 2014, Lassen et al., 2007, Pappa et al., 2005, 67 
Pappa et al., 2001, Stagos et al., 2010). However, ALDHs have gained even more 68 
attention, after their correlation with normal and cancer stem cell (CSC) populations 69 
(Gasparetto et al., 2012). In particular, the aldehyde dehydrogenase 1 (ALDH1) 70 
isoform was found to be  critical  for the isolation of cancer cells with stem-like 71 
features like self-renewal capacity, low proliferation rate, chemo-/radioresistance and 72 
enhanced clonogenic and tumorigenic potential (Calderaro et al., 2014, Croker and 73 
Allan, 2012, Deng et al., 2010, Lee et al., 2011, Sullivan et al., 2010, Yan et al., 74 
2014). Moreover, increased expression of ALDH was also used as an index for the 75 
isolation of tumor cell subpopulations with stem-like characteristics in addition to 76 
being associated with poor clinical outcome (Lee, Kim, 2011, Sullivan, Spinola, 77 
2010).  In this context, ALDH3A1 has been described as “tumor-associated aldehyde 78 
dehydrogenase” (T-ALDH) (Lin et al., 1988) and has been shown to be upregulated in 79 
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several cancer types (Parajuli et al., 2014, Patel et al., 2008). Finally, only recently,  it 80 
has been postulated to possess additional functional roles in stem cell biology in 81 
respect to self-protection, differentiation and cellular expansion (Ma and Allan, 2011).   82 
However, there are not many studies suggesting how exactly the over-expression of 83 
ALDH is utilized as a CSC marker and in particular what might be the underlying 84 
mechanism(s) of such involvement.  For these reasons, we established an isogenic 85 
MCF-7 cell line pair (differing only in the expression of human ALDH3A1) with the 86 
aim to (i) investigate into the effects of ALDH3A1 on cell viability and colony 87 
formation efficiency under various exogenous stresses, like chemotherapeutics, 88 
hydrogen peroxide (H2O2) and gamma-irradiation) and (ii)  to identify specific  gene 89 
profiles attributed to such acquired CSC-like traits. 90 
 91 
2. Materials and Methods 92 
2.1 Materials 93 
Human breast adenocarcinoma cell line MCF-7 was purchased from ATCC 94 
(Manassas, VA, USA). All of the standard culture media, fetal bovine serum (FBS), 95 
antibiotics and trypsin were either from Gibco (Life Technologies, Carlsbad, CA, 96 
USA), Biosera (East Sussex, UK), Biochrome (Berlin, Germany) or Sigma-Aldrich 97 
Co. (Taufkirchen, Germany). Lipofectamine and related transfection reagents were 98 
obtained from Life Technologies (Carlsbad, CA, USA) while hygromycin and 99 
protease inhibitors were from Carl Roth GmbH (Karlsruhe, Germany). Polyvinylidene 100 
difluoride (PVDF) membranes were purchased from Millipore (Bedford, MA, USA) 101 
and chemiluminescence reagents and BCA Protein assay kit were from Thermo 102 
Scientific (Rockford, IL, USA). Autoradiography films were obtained from Genesee 103 
Scientific (San Diego, CA, USA). All chemotherapeutic agents were from Sigma-104 
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Aldrich Co. (Taufkirchen, Germany) except 4-hydroxyperoxycyclophosphamide 105 
which was ontained from SantaCruz (Santa Cruz, California). Primers, dNTPs, Trizol 106 
and Platinum SYBR Green, were purchased from Invitrogen (Life Technologies 107 
Carlsbad, CA, USA) while random hexamers and PrimeScript Reverse Transcriptase 108 
were from Takara (Shiga, Japan). Rabbit polyclonal antibody against human 109 
ALDH3A1 was obtained from Abgent (San Diego, CA, USA). Mouse monoclonal 110 
antibody against EpCAM was from Cell Signalling Technology (Danvers, MA, 111 
USA). Goat anti-rabbit and mouse IgG horseradish peroxidase conjugated antibodies 112 
were obtained from Millipore (Bedford, MA, USA). CF488A goat anti-mouse IgG for 113 
immunofluorescence was from Biotium (Hayward, CA, USA). Unless stated 114 
otherwise, all other chemicals were purchased from Sigma-Aldrich Co. (Taufkirchen, 115 
Germany), Carl Roth GmbH (Karlsruhe, Germany) or Applichem (Darmstadt, 116 
Germany).  117 
 118 
2.2 Cell Culture 119 
Human breast cancer cell line MCF-7 was maintained in Dulbecco’s modified Eagle’s 120 
medium (DMEM) supplemented with 10% FBS, 100μg/ml streptomycin, and 121 
100units/ml penicillin. MCF-7 stable transfected cell lines were cultured in the same 122 
medium in the presence of 0.2mg/ml hygromycin. Cells were cultivated at 37°C with 123 
5% CO2 in a humidified incubator.   124 
 125 
2.3 Stable Transfection 126 
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The full-length human ALDH3A1 was subcloned into a suitable mammalian 127 
expression vector constructed as previously described (Bunting and Townsend, 128 
1996a,b, Pappa, Chen, 2003a).  MCF-7 cells (10
6
) were transfected with 16 µg 129 
ALDH3A1/vector or control vector using the Lipofectamine 2000 reagent. Stably 130 
transfected cells were selected in the presence of 0.2mg/ml of hygromycin in the 131 
culture medium 48h post transfection. Selected clones were isolated, expanded and 132 
maintained in the presence of hygromycin. 133 
 134 
2.4 Immunoblot analysis 135 
Cell lysates were prepared in 50mM Tris-HCl, pH 8.0 containing NaCl, 1% Nonidet 136 
P4O, and the protease inhibitors: 100μg/ml PMSF, 0.5μg/ml leupeptin, 0.5μg/ml 137 
aprotinin and 1μg/ml pepstatin A. Protein concentration was determined by the BCA 138 
assay. Cell lysates (30μg of total protein) were separated by SDS-PAGE 139 
electrophoresis and transferred to 0.2 µM PVDF membranes. The blots were blocked 140 
with 5% (w/v) BSA in TBST buffer (100mM Tris, pH 7.5, containing 150mM NaCl, 141 
and 0.1% v/v Tween-20) (blocking buffer) for 2 hours. Primary antibodies were used 142 
at different dilutions as follows: Polyclonal anti-ALDH3A1 and monoclonal anti-143 
EpCAM were used at dilutions of 1:500 and 1:5000 in blocking buffer respectively 144 
(overnight, 4°C). Secondary horseradish peroxidase conjugated goat anti-rabbit and 145 
mouse antibodies were used at a dilution of 1:5000 in blocking buffer (1-hour 146 
incubation, RT).  Signals were detected using the Supersignal West Pico 147 
Chemiluminescent Substrate. 148 
 149 
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2.5 Aldehyde dehydrogenase enzymatic activity assay 150 
The enzymatic activity of ALDH3A1 was estimated as described previously (Pappa, 151 
Estey, 2003b). Briefly, a mixture of 75mM Na-pyrophosphate, pH 8.0 containing 152 
1mM pyrazole, 2.5mM NADP
+
 and 50μl of cell lysates was prepared and used as a 153 
blank. The reaction was initiated by the addition of 0.5mM benzaldehyde. NADPH 154 
production was monitored for 5 min by the increase in the absorbance at 340nm with 155 
a Biochrom Libra S22 UV/visible spectrophotometer (Biochrom, Cambridge, UK).  156 
Finally, ALDH3A1 enzymatic activity was expressed as nanomoles of NADPH 157 
produced per minute, per mg of protein by taking into consideration the molar 158 
extinction coefficient of NADPH (6.22mM
-1
/cm
-1
). 159 
 160 
2.6 Colony Formation Assay 161 
Approximately 600 cells were plated in 10-cm culture dishes and subjected to various 162 
doses (0 to 10 Gray) of gamma radiation (Cobalt 60). Subsequently, cells were placed 163 
in a humidified incubator (37°C, 5% CO2) and were monitored on a daily basis up to 164 
the formation of visible colonies (usually two weeks later). Cells were then fixed and 165 
stained with 0.5% of crystal violet solution diluted in 25% methanol. Colonies 166 
containing ≥50 of cells were counted using a stereomicroscope and digital images 167 
were obtained by camera or scanner and counted using ImageJ software. 168 
 169 
2.7 Sulforhodamine B (SRB) assay 170 
SRB assay was conducted as described earlier (Lassen et al. , 2006). Briefly, MCF-171 
7/mock and MCF-7/ALDH3A1 cells were seeded in 96-well culture plates and then 172 
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were treated, in triplicates, with 4-hydroxyperoxycyclophosphamide, etoposide, 173 
doxorubicin, 5-fluorouracil, and H2O2. All chemotherapeutic agents were initially 174 
prepared in DMSO (or water in the case 4-hydroxyperoxycyclophosphamide) (as 175 
stock solutions of 50mM) and subsequently diluted (in cell culture medium) into 176 
various working concentrations: 4-hydroxyperoxycyclophosphamide (0-1600μM), 177 
etoposide (0-500μM), doxorubicin (0-1000μM), 5-fluorouracil (0-175μM). The 178 
working concentrations of H2O2 were 0-1000μM, and water was used as a vehicle. 179 
After a72-h incubation, cells were fixed with 50% (w/v) trichloroacetic acid (TCA) 180 
for 1h at 4
°
C, washed 5 times with water and stained with 0.4% (w/v) SRB diluted in 181 
1% acetic acid for 30 min. The excess dye was removed by washing with 1% (v/v) 182 
acetic acid. Plates were dried overnight, and the protein-bound dye was dissolved in 183 
10mM Tris base solution. Optical density was determined at 492nm by using a 184 
microplate reader (Tecan Xflour 4). Controls were vehicle-treated cells. Sigma Plot 185 
software (version 10) was used for estimating the EC50 values through the regression 186 
analysis via the four-parameter logistic curve as previously described (Anestopoulos 187 
et al., 2013). 188 
 189 
2.8 Real-time PCR 190 
Total RNA was extracted using Trizol reagent according to the manufacturer’s 191 
instructions. For cDNA synthesis, 4.5μg of total RNA with 1 mM dNTPs and 50pmol 192 
of random hexamers were used. For real-time PCR analysis, Platinum SYBR Green 193 
was used according to the manufacturer’s instructions. Reactions were carried out on 194 
an Applied Biosystems Step One Instrument. The sequences of the primers are 195 
provided in Table 1.  Reactions were run in triplicate in three independent 196 
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experiments. Expression data were normalized to beta-actin using the 2
-ΔΔCT
 method 197 
described by Livak and Schmittgen, 2001. 198 
 199 
2.9 Immunofluorescence 200 
Cells (1.5x10
5
) grown in a monolayer on the surface of coverslips were fixed 24-h 201 
post plating with 4% formaldehyde in phosphate-buffered saline (PBS) (for 20 min) 202 
and washed three times with PBS. Formaldehyde was neutralized by the addition of 203 
1M of Glycine (pH 8.5). Cells were permeabilized with 0.1% Triton Χ-100  followed 204 
by blocking with 5% BSA in PBS. The primary anti-EpCAM antibody was used at a 205 
dilution of 1:800 (1h, RT) whereas the secondary  (CF488A goat anti-mouse) was 206 
used at a dilution of 1:250, in PBS, for 30 min. Nuclei were counterstained with 4'-6-207 
diamidino-2-phenylindole (DAPI) (1 μg/ml) and washed three times with PBS. 208 
Finally, cells were mounted with MOWIOL (Calbiochem, Bad Soden, Germany) and 209 
imaged with a 60x/NA 1.45 oil immersion objective and an Andor Ixon+885 digital 210 
camera on a customized Andor Revolution Spinning Disk Confocal System built 211 
around an IX81; Olympus stand (CIBIT Facility, MBG-DUTH). Andor IQ 2.7.1 212 
software was used for image acquisition and analysis.  213 
 214 
2.10 Statistical analysis 215 
At least three independent experiments were conducted per sample for each 216 
condition tested. All values were  expressed as mean ± S.E. Comparison of results 217 
between two groups was performed by Student’s t-test. Differences between 218 
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individual groups were assessed by a Dunnett post hock test. Prism software (version 219 
5) was used for all statistical analyses. A value of p<0.05 was considered significant.  220 
 221 
3. Results 222 
3.1 Generation and characterization of the MCF-7 isogenic cell line pair  223 
Stable transfection of the human ALDH3A1 cDNA in MCF-7 cells resulted in the 224 
selection of two ALDH31/MCF-7 clones (Figure 1). Clone #2 with the highest 225 
ALDH3A1 expression levels (confirmed by western blot analysis; Figure 1A) was 226 
chosen for all subsequent experiments and thus designated as ALDH3A1/MCF-7. 227 
Furthermore, expression of ALDH3A1 was also confirmed by real-time PCR (>100-228 
fold in mRNA levels compared to mock/ALDH3A1 cells; Figure 1B). Enzymatic 229 
activity, in ALDH3A1/MCF-7 cells, was estimated to be 535±16 units/min/mg 230 
whereasMock/ALDH3A1 cells exhibited negligible activity (Figure 1C). Regular 231 
monitoring of the enzymatic activity confirmed the maintenance of stable ALDH3A1 232 
expression. Finally, it was observed that  ALDH3A1/MCF-7 cells had considerably 233 
slower cycling capacity when compared to mock ones and estimated that their colony 234 
formation efficiency was approximately 57% of that of control cells (Figure 1D).  235 
 236 
3.1 Expression of ALDH3A1 confers chemoresistance to MCF-7 cells  237 
Next, we sought to determine the response of this isogenic cell line pair to various 238 
chemotherapeutic agents characterized by different modes of actions. Mock/ and 239 
ALDH3A1/MCF-7 cells were incubated for 72 h with increasing concentrations of 4-240 
hydroxyperoxycyclophosphamide (an active derivative of cyclophosphamide), 241 
doxorubicin, etoposide, 5-fluorouracil and SRB-based cell viability curves were 242 
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plotted (Figures 2A-D respectively). Our data demonstrate that ALDH3A1 was 243 
associated with a chemoresistant phenotype as indicated by the cell viability curves in 244 
ALDH3A1-expressing cells compared to the non-expressing (mock) cells, under all 245 
treatments. ALDH3A1/MCF-7 cells exhibited approximately 2-fold resistance to 4-246 
hydroxyperoxycyclophosphamide, (Figure 1A), ~11-fold resistance to doxorubicin 247 
(Figure 2B), 8-fold resistance to etoposide  (Figure 2C), and 2-fold resistance to 5-248 
fluorouracil (Figure 2D) when compared to mock cells.   249 
 250 
3.2 Expression of ALDH3A1 confers resistance to radiation- and H2O2-induced 251 
cytotoxicity  252 
Next, we investigated on the response of the isogenic cell line pair to other cytotoxic 253 
agents like H2O2 and gamma radiation. ALDH3A1 expression was associated with 254 
increased tolerance to H2O2-induced cytotoxicity (Figure 3A). Interestingly, following 255 
72 h incubation with a range of H2O2 concentrations (up to 1mM) viability in 256 
ALDH3A1/MCF-7 cells did not fall below 60% when compared to control (untreated) 257 
cells. On the contrary, mock/MCF-7 cells sustained roughly 10% viability under the 258 
same experimental conditions (Figure 3A). Although the average EC50 value for mock 259 
cells was estimated around 92μM, we were unable to calculate an accurate EC50 value 260 
for ALDH3A1/MCF-7 cells in the same range of H2O2 concentrations (Figure 3A).  261 
Data from colony formation collected up to two weeks post-irradiation with a range of 262 
gamma irradiation (e.g. up to 10 Gy) revealed that ALDH3A1 contributed 263 
significantly to the maintenance of colony formation under radiation stress (Figure 264 
3B).  265 
 266 
13 
 
3.3 ALDH3A1 alters gene expression profile in MCF-7 cells 267 
The resistant phenotype of ALDH3A1/MCF-7 cells together with the observation of 268 
being slow cycling cells led to the evaluation of whether ALDH3A1 expression 269 
caused any alterations in the genetic make-up of MCF-7 cells. Thus, we analyzed the 270 
expression profile of several cell cycle regulatory proteins together with proteins-271 
pumps that modulate drug import/export processes in the cell. Because slow cycling 272 
and chemotherapy/radiation resistance have been described as common traits for 273 
cancer stem cells (Alison et al., 2011, Ghaffari, 2011), we investigated the gene 274 
expression levels of those potentially relevant cancer stem cell markers including  275 
CXCR4, Notch1, SOX2, Oct4, JAG1, EpCAM, and CD49f. qRT-PCR experiments 276 
showed that the gene expression levels of cell cycle regulatory proteins (e.g. cyclins 277 
A,  B1, and B2) were up-regulated while cyclin D and p21 were down-regulated. No 278 
significant changes were observed for cyclin E and p53 (Figure 4A). We also 279 
examined the effects of ALDH3A1 on the expression of the ATP-binding cassette 280 
(ABC) transporters ABCA2, ABCB1 (P-glycoprotein 1 or Multidrug Resistant 281 
Protein 1) and ABCG2 (Breast Cancer Resistance Protein 1). ALDH3A1 expression 282 
did not affect the expression levels of ABCA2 and ABCB1, whereas a slight decrease 283 
was observed for ABCG2 (Figure 4B).  Significant changes were observed for all 284 
cancer stem cell markers tested in a manner where CXCR4, Notch1, SOX2, Oct4, and 285 
JAG1 were significantly down-regulated whereas the epithelial cell adhesion 286 
molecules EpCAM and CD49f (integrin subunit alpha 6) were up-regulated in  287 
ALDH3A1/MCF-7 cells (Figure 4C).  To further validate the RT-PCR results, we 288 
selected the epithelial adhesion molecule EpCAM to confirm its up-regulation by both 289 
immunofluorescence and immunoblotting. Indeed, Figure 4D depicts enhanced 290 
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immunofluorescent localization of EpCAM in the ALDH3A1/MCF-7 cells while 291 
Western  blotting also confirmed previous findings (Figure 4E). 292 
 293 
4. Discussion  294 
ALDHs represent a family of proteins implicated in cellular homeostasis in addition 295 
to their metabolic role (Pappa, Estey, 2003b). Indeed, a variety of ALDH isoforms are 296 
referred to as (i) corneal/lens crystallins (structural and protective components of 297 
cornea/lens) (Estey, Piatigorsky, 2007), (ii) cell protectors against ischemia-induced 298 
cardiac damage (Budas et al., 2010, Luo et al., 2014), (iii) modulators of cell 299 
proliferation rates (Lassen, Pappa, 2006, Liu et al., 2014, Pappa, Brown, 2005, Pappa, 300 
Chen, 2003a, Zhang et al., 2014) and (iv) mediators of differentiation in normal and 301 
cancer cells asserting to be markers of cell “stemness” (Balber, 2011, Dolle et al., 302 
2015). In particular, correlation of ALDHs with normal/cancer stem cells is not recent 303 
with reports dating back to 1980s describing an association between leukemic cells 304 
overexpressing ALDHs and resistance to cyclophosphamide (Russo and Hilton, 1988, 305 
Tsukamoto et al., 1998). At the time and while studies were focused on the enzymatic 306 
activity specificities of ALDHs (capable of detoxifying cyclophosphamide), it was 307 
soon discovered that ALDHs expression was also a characteristic of healthy 308 
progenitor hematopoietic cells but was gradually lost during the maturation process to 309 
lymphocytes (Kastan et al., 1990). Since then, ALDHs (alone or in combination with 310 
other known markers) were considered a valuable marker for isolating hematopoietic 311 
progenitor populations (Armstrong et al., 2004, Fallon et al., 2003, Hess et al., 2004, 312 
Storms et al., 1999). Furthermore, their usage as a putative stem cell marker was also 313 
extended to the neuronal system (Balber, 2011, Cai et al., 2004, Corti et al., 2006a, 314 
Corti et al., 2006b). Less than a decade ago, ALDHs were studied more extensively 315 
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and thus were proposed as CSC markers, initially in leukemias and later in cases of 316 
solid tumours (Cheung et al., 2007, Pearce et al., 2005). Until now, ALDHs utilization 317 
as CSC markers have been investigated in a broad range of different cancers and in 318 
most cases, ALDHs expression was found to be a promising marker for the 319 
discrimination of sub-populations with stem-like characteristics (Chen et al., 2010, 320 
Deng, Yang, 2010, Emmink et al., 2011, Gong et al., 2010, Liang and Shi, 2012, 321 
Marcato et al., 2011, Shien et al., 2012, Sullivan, Spinola, 2010, Wang et al., 2012). 322 
On the other hand, there is still a long way to identifying specific ALDHs isoforms 323 
responsible for different types of cancer in addition to determining variable potential 324 
cancerous stem cell sub-population properties and qualities. Thus, elucidating the 325 
underlying mechanisms of ALDHs over-expression in CSCs is of crucial importance 326 
in tumor biology. 327 
On another note, ALDH3A1 exhibits a distinct expression pattern. It is inducible by 328 
xenobiotics in the liver and constitutively expressed in certain epithelial tissues like 329 
lung, stomach, skin, and cornea. In the latter, its constitutive expression can reach up 330 
to 40% of the water-soluble proteins thus classifying ALDH3A1 as a corneal 331 
crystallin (Estey et al., 2010, Lassen, Bateman, 2007, Reisdorph and Lindahl, 2007). 332 
In fact, ALDH3A1 is a characteristic example of the multi-functional nature  of the 333 
ALDH family as its expression has been associated with an apparent cell survival 334 
advantage under various stress conditions thus implicating ALDH3A1 as being a 335 
significant element in major homeostatic mechanisms including cell regulation and 336 
apoptosis (Estey, Piatigorsky, 2007, Pappa, Chen, 2003a). To examine the putative 337 
role of ALDH3A1 in the development of CSCs properties, we established MCF-7 338 
cells are over-expressing ALDH3A1 and studied its impact on stem cell–like 339 
properties. CSCs are relatively resistant to radiation as well as chemotherapeutic 340 
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agents like carboplatin, etoposide, fluorouracil, paclitaxel, daunorubicin, 341 
mitoxantrone, cyclophosphamide, temozolomide, and gemcitabine (Dylla et al., 2008, 342 
Hermann et al., 2007, Liu et al., 2006, Ma et al., 2008, Todaro et al., 2007, Wulf et al., 343 
2001). Interestingly, our results indicated that ALDH3A1 protects MCF-7 cells from 344 
the cytotoxic effects of a wide variety of commonly used chemotherapeutic agents 345 
like 4-hydroxyperoxycyclophosphamide, etoposide, doxorubicin and 5-fluorouracil 346 
(Horak et al., 2013, Lekakis et al., 2012, Loi et al., 2013, Moitra et al., 2012). Indeed, 347 
previous studies have documented up-regulation of ALDHs with enhanced 348 
chemoresistance in breast cancer cells both in vitro and in vivo (Cioce et al., 2014, 349 
Croker and Allan, 2012, Lee, Kim, 2011). The results are in accordance with previous 350 
studies that have shown that overexpression of ALDH3A1 results in resistance to 4-351 
hydroxyperoxycyclophosphamide and  other active metabolites of cyclophosphamide 352 
[Bunting et al. J Biol Chem. 1994, 269: 23197-23203, Moreb et al., 2007). 353 
Interestingly, increased resistance to doxorubicin  has also been associated with the 354 
ectopic expression of other ALDH members (Moreb et al., Chem. Biol. Interact., 355 
2012, 195: 52-60),  which is possibly mediated  through indirect mechanisms by 356 
modulating  oxidative stress response as previously reported for ALDH3A1 in 357 
relation to resistance to mitomycin C and etoposide (Pappa A et al., J. Biol. Chem. 358 
2005, 280: 27998–28006). Moreover, ALDH3A1/MCF-7 cells exhibited enhanced  359 
survival and colony formation capacities in the presence of additional stress factors 360 
like gamma radiation and exposure to H2O2. Certainly, the specificity of ALDH3A1 361 
for the metabolism and detoxification of cyclophosphamide (Bunting and Townsend, 362 
1996b) and 4-HNE (Pappa, Estey, 2003b) is an important contributing factor 363 
underlining resistance, but its ability to  protect adequately against a variety of other 364 
stressors supports the notion for an overall, multi-mode resistance phenotype 365 
17 
 
characteristic of ALDH3A1/MCF-7 cells. One possible mechanism accountable for 366 
the apparent resistance of these cells would be their slow-growing rate. This is in 367 
accordance with another study where ALDH3A1 led to inhibition of proliferation, 368 
slower cell cycling rates, and lower colony formation efficiency expression in human 369 
corneal epithelial cells (Estey, Piatigorsky, 2007, Pappa, Brown, 2005). This anti-370 
proliferative action of ALDH3A1 was also observed in our study where the 371 
ALDH3A1/MCF-7 cells had the capacity to form only about 57% of the colonies 372 
formed in mock/MCF-7 cells. In general, CSCs are slow-growing cells in the 373 
quiescent state and consequently resistant to drugs designed to target fast-growing 374 
cancer cells (Dalerba et al., 2007, Tirino et al., 2013, Vinogradov and Wei, 2012). To 375 
characterize the molecular mechanisms responsible for the slow proliferation rates 376 
observed, we analyzed the gene expression profile of key cell cycle regulatory 377 
proteins. We noticed that ALDH3A1-expressing MCF-7 cells exhibited an (i) up-378 
regulation of cyclins A, B1, B2 and (ii) down-regulation of cyclin D1 and 379 
transcription factor p21. Previous studies demonstrated that protein levels of cyclins 380 
A, B, E, E2F1, and p21, as well activities of cyclin A- and cyclin B- dependent 381 
kinases were all decreased in ALDH3A1/HCE cells (Pappa, Brown, 2005). While it is 382 
true that the comparative qPCR method used in this study detects differences only at 383 
the transcriptional level, the differential expression pattern of major cell cycle 384 
regulatory proteins (also previously reported for ALDH3A1-expressing HCE cells) 385 
may account for the slow proliferation phenotype observed. On the other hand, there 386 
are also reports associating knock down of ALDH3A1 in lung cancer cells with slower 387 
growth (Moreb et al., 2008). To this end, findings so far appear contradictory, and 388 
although they may reflect tissue-specific issues or differences in biology between 389 
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normal and cancer cells, they urge the need for further investigations towards the 390 
clarification of the role of ALDH3A1 in cell proliferation. 391 
The possibility that drug resistance displayed by the ALDH3A1-expressing cells is 392 
likely due to enhanced expression of transporters that mediate chemotherapeutic drug 393 
efflux (Gottesman et al., 2002, Ween et al., 2015) was excluded. In general, several 394 
types of ABC transporters are known to be over-expressed in a variety of cancers 395 
where they are responsible for the development of chemoresistance (Chang et al., 396 
2009, Doyle and Ross, 2003, Gottesman, Fojo, 2002, Mack et al., 2008). However, no 397 
detectable changes were observed in mRNA levels of ABCA2 and ABCB1 protein 398 
pumps. On the contrary, only a minor decrease observed for the ABCG2 pump in the 399 
ALDH3A1-expressing cells compared to mock. Another possible mechanism for the 400 
observed chemo-/radioresistance, in the presence of ALDH3A1, would be through 401 
mediating DNA damage checkpoint response. Indeed, increased activation of the 402 
DNA damage checkpoint response has been associated with expression of ALDH3A1 403 
in corneal epithelial cells and preliminary data (obtained in our lab) certainly points 404 
towards this direction (data not shown). Similarly, the resistance of glioblastoma 405 
CSCs to irradiation has been attributed to increased activation of the DNA damage 406 
checkpoint (Bao et al., 2006).  407 
To better characterize the changes caused by ALDH3A1 on gene expression, we 408 
investigated the presence of presumed protein markers found to be up-regulated in 409 
CSCs. The gene expression profile was significantly differentiated between the two 410 
MCF-7 isogenic cell lines. The mRNA levels of CXCR4, Notch1, SOX2, SOX4, 411 
OCT4, and JAG1, displayed down-regulation whereas EpCAM and CD49F were 412 
significantly up-regulated in the ALDH3A1/MCF-7 cells. We further validated the 413 
expression of the epithelial cell adhesion molecule (EpCAM) by immunofluorescence 414 
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and immunoblotting and showed that EpCAM protein levels were substantially 415 
elevated in the ALDH3A1 expressing MCF-7 cells. EpCAM together with CD49F 416 
have been studied extensively for their functional roles and usage as potential CSCs 417 
markers (Cariati et al., 2008, Deng et al., 2015, Guo et al., 2012, Guo et al., 2014, 418 
Wang et al., 2011). EpCAM is suggested to provide a sustained proliferative signal to 419 
cancer-initiating and normal stem cells where it is overexpressed. Cancer cells appear 420 
to benefit from the constitutive expression of EpCAM for proliferation, self-renewal, 421 
and anchorage-independent growth and invasiveness (Munz et al., 2009). On the other 422 
hand, CD49F (also known as a6 integrin) plays a significant role in cell adhesion. Its 423 
high expression in mammary epithelial cells is associated with progenitor and stem 424 
cell activity (Goel et al., 2014). This integrin acts as an adhesion receptor for the 425 
mammary epithelial cells mediating developmental signals and assisting cells in 426 
sensing growth factor and hormonal signals (Kaimala et al., 2012). It appears to play a 427 
major role in sustaining the survival of mammary carcinoma cells especially under 428 
stress conditions such as those existing in the tumor microenvironment (Chung and 429 
Mercurio, 2004).  430 
In conclusion, MCF-7 cells over-expressing ALDH3A1 demonstrated low 431 
proliferation rates associated with a resistant phenotype against various sources of cell 432 
stress including exposure to various chemotherapeutics, gamma radiation, and H2O2 433 
insult. Furthermore, they displayed differential expression of proteins involved in cell 434 
cycle regulation and increased expression of the cell adhesion molecules CD49f and 435 
EpCAM. Although the precise mechanisms remain unclear, our findings provide 436 
considerable implications on defining the biological significance of ALDH3A1 in cell 437 
homeostasis.  438 
 439 
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FIGURE LEGENDS 450 
Figure 1: Characterization of the MCF-7 isogenic cell line pair. A. Western blot 451 
analysis of ALDH3A1 expression: Lane 1: recombinant ALDH3A1 (1 μg), lanes 2-7: 452 
30 µg cell extracts,  2; parental MCF-7, 3-4; mock-transfected ALDH3A1, 6-7: 453 
ALDH3A1/MCF-7 transfected clones. B. ALDH3A1 gene expression levels detected 454 
by real-time PCR in mock/ and ALDH3A1/MCF7. C.  Enzymatic activity of 455 
ALDH3A1 in mock/MCF-7 and ALDH3A1/MCF-7 cells. Results are expressed as 456 
means of a minimum of three independent experiments ± SE. D. Colony formation 457 
efficiency of mock and ALDH3A1/MCF-7 cells.  Cells (600) were seeded in 10 cm 458 
culture dishes and were allowed to form colonies for two weeks in a humidified 459 
incubator that were subsequently counted following crystal violet staining by using 460 
Image J. Results are expressed as mean ±S.E of three independent experiments. *** 461 
p<0.001.  462 
Figure 2: Effect of various chemotherapeutic agents on cell viability of mock/ 463 
and   ALDH3A1/MCF-7 cells.  464 
Viability curves of mock/ and ALDH3A1/MCF-7 cells along with the calculated half 465 
maximal effective concentrations (EC50 values) of (A) 4-466 
hydroxyperoxycyclophosphamide, (B) doxorubicin, (C) etoposide, and (D) 5-467 
fluorouracil are represented. Viability curves of the ALDH3A1/MCF-7 cells are 468 
shifted to the right indicating increased tolerance of the cells to the cytotoxic effect of 469 
the agents used. Results are shown as mean ± S.E. At least three independent 470 
experiments were performed for each condition. * p<0.05, ** p<0.01, *** p<0.001 471 
 472 
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Figure 3: Effect of H2O2 and gamma radiation on the viability of mock/ and 473 
ALDH3A1/MCF-7 cells. The viability curves of mock/ and ALDH3A1/MCF7 cells 474 
along with the half maximal effective concentrations (EC50 values) of (A) H2O2 and 475 
(B) gamma radiation are presented. ALDH3A1 expression is associated with 476 
increased tolerance to the cytotoxic effects of H2O2 and gamma radiation. Results are 477 
presented as mean ± SE of three independent experiments. * p<0.05, ** p<0.01, *** 478 
p<0.001 479 
 480 
Figure 4: Expression of ALDH3A1 alters gene profiling in ALDH3A1/MCF-7 481 
cells.  Effect of ALDH3A1 on the gene expression of (A) cycle cell regulatory 482 
proteins (B) Membrane ABC transporters (C) Cancer stem cell markers. The 483 
comparative quantification ΔΔCt method was utilized for analyzing the fold change of 484 
gene expression. Beta-actin gene was used as endogenous control for the 485 
normalization of samples. D: Immunofluorescence for EpCAM (green) in 486 
ALDH3A1/MCF-7 (i) and mock/MCF-7 (ii) cells. No secondary antibody for 487 
EpCAM was used in the negative control (iii), whereas nuclei were stained with DAPI 488 
(4’,6-diamino-2-phenylindole) (blue).  E. Western blotting analysis for EpCAM in 489 
mock and ALDH3A1/MCF-7 cells. Results are shown as mean ± S.E. At least three 490 
independent experiments were performed for each condition. * p<0.05, ** p<0.01, 491 
*** p<0.001 492 
  493 
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Table 1. Primers used for the real-time PCR comparative quantification  494 
 495 
 496 
GENE FORWARD PRIMER REVERSE PRIMER 
β-actin GCGCGGCTACAGCTTCA CTTAATGTCACGCACGATTTCC 
ALDH3A1 CAGCGGCATGGGATCCTA GCGGCGGTGAGAGAAAGTC 
Cyclin A 
ACGGGTTGCACCCCTTAAG 
 
CCAAGGAGGAACGGTGACA 
 
Cyclin B1 
GGCCTCTACCTTTGCACTTCCT 
 
GCTCGACATCAACCTCTCCAA 
 
Cyclin B2 
AAGCTTTTTCTGATGCCTTGCT 
 
AGGGTTCTCCCAATCTTCGTTAT 
 
Cyclin D 
AGACCTTCGTTGCCTCTTGTG 
 
ATGGAGGGCGGATTGGAA 
 
Cyclin E 
GGCCTTGTATCATTTCTCGTCAT 
 
CGCACCACTGATACCCTGAA 
 
p53 
TCTGTCCCTTCCCAGAAAACC 
 
CAAGAAGCCCAGACGGAAAC 
 
p21 
GGCGGGCTGCATCCA 
 
AGTGGTGTCTCGGTGACAAAGTC 
 
ABCA2 
AGATGGACAAGATGATCGAG 
 
GCTTGTACTTCAGGATGAGG 
 
ABCB1 
GAGGAAGACATGACCAGGTA 
 
CTGTCGCATTATAGCATGAA 
 
ABCG2 
ACCTGAAGGCATTTACTGAA 
 
TCTTTCCTTGCAGCTAAGAC 
 
CXCR4 
GGCCGACCTCCTCTTTGTC 
 
TTGCCACGGCATCAACTG 
 
Notch1 
GCACCTCAGCCTGCACAGT 
 
CTGTGTTGCTGGAGCATCTTCT 
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SOX2 
TGCGAGCGCTGCACAT 
 
TCATGAGCGTCTTGGTTTTCC 
 
SOX4 
CTGCGCCTCAAGCACATG 
 
 
TTCTTCCTGGGCCGGTACT 
 
Oct4 
CGACCATCTGCCGCTTTG 
 
GCCGCAGCTTACACATGTTCT 
 
JAG1 
TGAAGTAGAAGAGGACGACATGGA 
 
CGGCTGCTTGGCAAACC 
 
EpCAM 
 
TTATGATCCTGACTGCGATGAGA 
 
GGTGCCGTTGCACTGCTT 
 
CD49F GATCCCGGCCTGTGATTAATATT CTGGCGGAGGTCAATTCTGT 
 497 
 498 
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 500 
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Table 1. Primers used for the real-time PCR comparative quantification  
 
 
GENE FORWARD PRIMER REVERSE PRIMER 
β-actin GCGCGGCTACAGCTTCA CTTAATGTCACGCACGATTTCC 
ALDH3A1 CAGCGGCATGGGATCCTA GCGGCGGTGAGAGAAAGTC 
Cyclin A 
ACGGGTTGCACCCCTTAAG 
 
CCAAGGAGGAACGGTGACA 
 
Cyclin B1 
GGCCTCTACCTTTGCACTTCCT 
 
GCTCGACATCAACCTCTCCAA 
 
Cyclin B2 
AAGCTTTTTCTGATGCCTTGCT 
 
AGGGTTCTCCCAATCTTCGTTAT 
 
Cyclin D 
AGACCTTCGTTGCCTCTTGTG 
 
ATGGAGGGCGGATTGGAA 
 
Cyclin E 
GGCCTTGTATCATTTCTCGTCAT 
 
CGCACCACTGATACCCTGAA 
 
p53 
TCTGTCCCTTCCCAGAAAACC 
 
CAAGAAGCCCAGACGGAAAC 
 
p21 
GGCGGGCTGCATCCA 
 
AGTGGTGTCTCGGTGACAAAGTC 
 
ABCA2 
AGATGGACAAGATGATCGAG 
 
GCTTGTACTTCAGGATGAGG 
 
ABCB1 
GAGGAAGACATGACCAGGTA 
 
CTGTCGCATTATAGCATGAA 
 
ABCG2 
ACCTGAAGGCATTTACTGAA 
 
TCTTTCCTTGCAGCTAAGAC 
 
CXCR4 
GGCCGACCTCCTCTTTGTC 
 
TTGCCACGGCATCAACTG 
 
Notch1 GCACCTCAGCCTGCACAGT CTGTGTTGCTGGAGCATCTTCT 
Table(s)
  
SOX2 
TGCGAGCGCTGCACAT 
 
TCATGAGCGTCTTGGTTTTCC 
 
SOX4 
CTGCGCCTCAAGCACATG 
 
 
TTCTTCCTGGGCCGGTACT 
 
Oct4 
CGACCATCTGCCGCTTTG 
 
GCCGCAGCTTACACATGTTCT 
 
JAG1 
TGAAGTAGAAGAGGACGACATGGA 
 
CGGCTGCTTGGCAAACC 
 
EpCAM 
 
TTATGATCCTGACTGCGATGAGA 
 
GGTGCCGTTGCACTGCTT 
 
CD49F GATCCCGGCCTGTGATTAATATT CTGGCGGAGGTCAATTCTGT 
 
 
